Skip to main content

Table 2 Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive patients combined

From: The Association of the COMT V158M Polymorphism with Endometrial/Ovarian Cancer in HNPCC Families Adhering to the Amsterdam Criteria

Group Val/Val (%) Val/Met (%) Met/Met (%) n Pearson's Chi-squared
subject group 86 (26.0) 167 (50.5) 78 (23.6) 331  
hMLH1 mutation carriers 48 (26.4) 91 (50.0) 43 (23.6) 182 p = 0.98
hMSH2 mutation carriers 38 (25.5) 76 (51.0) 35 (23.5) 149  
mutation type: truncation/deletion 76 (26.7) 144 (50.5) 65 (22.8) 285 p = 0.65
mutation type: missense 10 (21.7) 23 (50.0) 13 (28.3) 46  
affected with CRC 38 (25.5) 79 (53.0) 32 (21.5) 149 p = 0.50
unaffected with CRC 47 (26.4) 84 (47.2) 47 (26.4) 178  
unaffected with CRC (>45 years) 15 (23.1) 35 (53.8) 15 (23.1) 65 p = 0.92**
endometrial/ovarian cancer 11 (29.7) 18 (48.6) 8 (21.6) 37 p = 0.66
affected with CRC and unaffected with endometrial/ovarian cancer* 50 (23.0) 112 (51.6) 55 (25.3) 217  
  1. *This group contained males and females. The sex was unknown for all of the patients.
  2. ** This group was compared to patients affected with CRC